Handa Pharmaceuticals (漢達) announced on the 13th that it has granted exclusive Taiwan marketing rights for its leukemia drug, PHYRAGO, to Taiwan Specialty Pharma Corp. (吉泰藥品).

Clinical Differentiation:

• Regulatory Pathway: PHYRAGO is a 505(b)(2) product launched in the US in October 2025.
• PK Advantage: Unlike conventional formulations of the same API, PHYRAGO maintains therapeutic bioavailability regardless of gastric pH. It shows no significant pharmacokinetic (PK) interference when co-administered with PPIs (Proton Pump Inhibitors) or H2RAs, solving a critical clinical pain point for Ph+ CML and Ph+ ALL patients who require acid suppression therapy.
• Strategic Synergy: Taiwan Specialty Pharma Corp brings an extensive distribution network across hematology, oncology, and nephrology in Taiwan, which Handa expects will accelerate market penetration and address significant unmet medical needs.

Resource: 漢達攜手吉泰藥品，搶食國內7億血癌藥市場